Long non-coding RNA (LncRNA) MRPL23-AS1 promotes tumor progression and carcinogenesis in osteosarcoma by activating Wnt/β-catenin signaling via inhibiting microRNA miR-30b and upregulating myosin heavy chain 9 (MYH9)

Abstract

Long non-coding RNA (LncRNA) contributes to the occurrence and development of osteosarcoma (OS), although the underlying mechanism is not clear. In the present study, we showed that lncRNA MRPL23-AS1 was remarkably increased in OS tissues and cell lines. Stable knockdown of MRPL23-AS1 evidently attenuated cell viability and invasive ability, meanwhile inhibited in vivo tumor growth and dissemination. In terms of mechanism, luciferase reporter, RNA pull-down and fluorescence in situ hybridization (FISH) assays showed that MRPL23-AS1 competitively interacted with miR-30b, increasing myosin heavy chain 9 (MYH9) expression, a trans- activator of β-catenin, resulting in the activation of Wnt/β-catenin pathway, thereby promoting OS tumorigenesis and metastasis. Importantly, high MRPL23-AS1 was positively correlated with MYH9, while conversely correlated with miR-30b, suggesting that the regulatory axis of MRPL23-AS1/miR-30b/MYH9 does exist in OS. Clinically, OS patients with high MRPL23-AS1 had larger tumor size, higher stage and easier metastasis than those with low MRPL23-AS1, moreover, MRPL23-AS1 was identified as an adverse prognostic factor for OS survival. In conclusion, our results show that MRPL23-AS1 is a key oncogenic lncRNA in OS, targeting of MRPL23-AS1 may be a promising treatment for OS patients.

Overexpressing long non-coding RNA OIP5-AS1 ameliorates sepsis-induced lung injury in a rat model via regulating the miR-128-3p/Sirtuin-1 pathway

“…Twenty-four hour prior to transfection, NR8383 cells in the logarithmic growth phase were seeded into 96-well microplates to achieve a fusion rate at 60–80%. In keeping with the manufacturer’s protocol, FuGENE® reagent (Promega, Madison, WI, USA) was applied for the transient transfection of plasmids (covering OIP5-AS1 overexpression plasmid or OIP5-AS1-NC) or miR-128-3p mimics and miR-NC (GenePharma, Shanghai, China) into NR8383 and RLE-6TN cells for 48 h, respectively [ 23 ]. Six hours following stimulation with lipopolysaccharide (LPS, Sigma-Aldrich) of different concentrations (25, 50, 100 ng/mL), NR8383 or RLE-6TN cells were harvested for further experiments.…”

MicroRNA hsa-miR-150-5p inhibits nasopharyngeal carcinogenesis by suppressing PYCR1 (pyrroline-5-carboxylate reductase 1)

“…After 48 h, firefly and Renilla luciferase activities were examined using the Luciferase Assay Kit (RG027, Beyotime, China). Renilla luciferase activity was used as an internal control [ 23 ].…”

Mesenchymal stem cell-derived extracellular vesicles prevent the development of osteoarthritis via the circHIPK3/miR-124-3p/MYH9 axis

“…MYH9, a class of MYH9 gene encoding “gastric” framework-related protein, is a hexamer composed of two 220 kDa heavy chains, two 17 kDa essential light chains, and two 20 kDa regulatory light chains, widely expressed in cells and tissues [ 78 – 80 ]. MYH9 has been confirmed to have vital regulatory effects in papillary thyroid cancer [ 81 ], osteosarcoma [ 82 ], gastric cancer [ 83 ], melanoma [ 84 ] and other diseases. However, the role of MYH9 in OA remains unknown previously.…”